Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, being characterized by a broad substrate spectrum that includes aminothiazoleoxime and cephalosporins such as cefotaxime. Moreover, strains harboring KPC-type β-lactamases are often reported as resistant to available β-lactamase inhibitors (clavulanic acid, tazobactam and sulbactam). Therefore, the identification of novel non β-lactam KPC-2 inhibitors is strongly necessary to maintain treatment options. This study explored novel, non-covalent inhibitors active against KPC-2, as putative hit candidates. We performed a structure-based in silico screening of commercially available compounds for non-β-lactam KPC-2 inhibitors. Thirty-two commercially available high-scoring, fragment-like hits were selected for in vitro validation and their activity and mechanism of action vs the target was experimentally evaluated using recombinant KPC-2. N-(3-(1H-tetrazol-5-yl)phenyl)-3-fluorobenzamide (11a), in light of its ligand efficiency (LE = 0.28 kcal/mol/non-hydrogen atom) and chemistry, was selected as hit to be directed to chemical optimization to improve potency vs the enzyme and explore structural requirement for inhibition in KPC-2 binding site. Further, the compounds were evaluated against clinical strains overexpressing KPC-2 and the most promising compound reduced the MIC of the β-lactam antibiotic meropenem by four fold.

In silico identification and experimental validation of hits active against KPC-2 β-lactamase / Klein, Raphael; Linciano, Pasquale; Celenza, Giuseppe; Bellio, Pierangelo; Papaioannou, Sofia; Blazquez, Jesus; Cendron, Laura; Brenk, Ruth; Tondi, Donatella. - In: PLOS ONE. - ISSN 1932-6203. - 13:11(2018), pp. 1-22. [10.1371/journal.pone.0203241]

In silico identification and experimental validation of hits active against KPC-2 β-lactamase

Linciano, Pasquale;Tondi, Donatella
Supervision
2018

Abstract

Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, being characterized by a broad substrate spectrum that includes aminothiazoleoxime and cephalosporins such as cefotaxime. Moreover, strains harboring KPC-type β-lactamases are often reported as resistant to available β-lactamase inhibitors (clavulanic acid, tazobactam and sulbactam). Therefore, the identification of novel non β-lactam KPC-2 inhibitors is strongly necessary to maintain treatment options. This study explored novel, non-covalent inhibitors active against KPC-2, as putative hit candidates. We performed a structure-based in silico screening of commercially available compounds for non-β-lactam KPC-2 inhibitors. Thirty-two commercially available high-scoring, fragment-like hits were selected for in vitro validation and their activity and mechanism of action vs the target was experimentally evaluated using recombinant KPC-2. N-(3-(1H-tetrazol-5-yl)phenyl)-3-fluorobenzamide (11a), in light of its ligand efficiency (LE = 0.28 kcal/mol/non-hydrogen atom) and chemistry, was selected as hit to be directed to chemical optimization to improve potency vs the enzyme and explore structural requirement for inhibition in KPC-2 binding site. Further, the compounds were evaluated against clinical strains overexpressing KPC-2 and the most promising compound reduced the MIC of the β-lactam antibiotic meropenem by four fold.
2018
29-nov-2018
13
11
1
22
In silico identification and experimental validation of hits active against KPC-2 β-lactamase / Klein, Raphael; Linciano, Pasquale; Celenza, Giuseppe; Bellio, Pierangelo; Papaioannou, Sofia; Blazquez, Jesus; Cendron, Laura; Brenk, Ruth; Tondi, Donatella. - In: PLOS ONE. - ISSN 1932-6203. - 13:11(2018), pp. 1-22. [10.1371/journal.pone.0203241]
Klein, Raphael; Linciano, Pasquale; Celenza, Giuseppe; Bellio, Pierangelo; Papaioannou, Sofia; Blazquez, Jesus; Cendron, Laura; Brenk, Ruth; Tondi, Do...espandi
File in questo prodotto:
File Dimensione Formato  
journal.pone.0203241.pdf

Open access

Descrizione: PDF
Tipologia: Versione pubblicata dall'editore
Dimensione 3.39 MB
Formato Adobe PDF
3.39 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1167510
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 8
social impact